Safety and Tolerability Study for Age-Related Macular Degeneration

Completed · Phase 1/Phase 2

Conditions studied: Neovascular Age-Related Macular Degeneration

In brief

Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.

Key facts

Study ID

NCT01485588

Run by

Iconic Therapeutics, Inc.

People needed

18

Starts

2010-12-01

Expected to finish

2012-03-01

Last updated by the study team

2020-11-06

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Rocky Mountain Eye Center, P.C. — Missoula, Montana, United States
• Retina & Vitreous Center of Southern Oregon, P.C. — Ashland, Oregon, United States
• Palmetto Retina Center — West Columbia, South Carolina, United States
• Retina Research Center — Austin, Texas, United States
• Valley Retina Institute, PA — McAllen, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.